{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:44Z","timestamp":1786984424355,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.antiviral.2010.11.006","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T04:24:12Z","timestamp":1290227052000},"page":"64-70","source":"Crossref","is-referenced-by-count":48,"title":["Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa\u2122)"],"prefix":"10.1016","volume":"89","author":[{"given":"Stefan","family":"Langhammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Koban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ellerbrok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2010.11.006_bib0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/BJ20031375","article-title":"The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication","volume":"381","author":"Andrade","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0010","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.3748\/wjg.v12.i32.5140","article-title":"Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: cytotoxic and biomolecular effects","volume":"12","author":"Azzariti","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0015","first-page":"2099","article-title":"PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner","volume":"3","author":"Bos","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/313491a0","article-title":"Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor","volume":"313","author":"Brown","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0025","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1128\/JVI.62.3.866-874.1988","article-title":"Deletion of the vaccinia virus growth factor gene reduces virus virulence","volume":"62","author":"Buller","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0042-6822(88)90635-6","article-title":"Cell proliferative response to vaccinia virus is mediated by VGF","volume":"164","author":"Buller","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0040","series-title":"The Orthopoxviruses","author":"Fenner","year":"1988"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0887-2333(01)00014-5","article-title":"Evaluation of hepatic subcellular fractions for Alamar blue and MTT reductase activity","volume":"15","author":"Gonzalez","year":"2001","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0050","doi-asserted-by":"crossref","first-page":"567486","DOI":"10.1155\/2009\/567486","article-title":"Clinical efficacy and toxicity of anti-EGFR therapy in common cancers","volume":"2009","author":"Harandi","year":"2009","journal-title":"J. Oncol."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2174\/156652405774962326","article-title":"Countermeasures to the bioterrorist threat of smallpox","volume":"5","author":"Jahrling","year":"2005","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0060","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.01303-07","article-title":"Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor","volume":"52","author":"Jordan","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0065","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1074\/jbc.M008210200","article-title":"Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway","volume":"276","author":"Jost","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0070","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1091\/mbc.12.5.1519","article-title":"Matrix-independent survival of human keratinocytes through an EGF receptor\/MAPK-kinase-dependent pathway","volume":"12","author":"Jost","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0075","doi-asserted-by":"crossref","first-page":"25838","DOI":"10.1074\/jbc.M400343200","article-title":"Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies","volume":"279","author":"Kim","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0080","doi-asserted-by":"crossref","first-page":"e10412","DOI":"10.1371\/journal.pone.0010412","article-title":"A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection","volume":"5","author":"Kramski","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0085","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1073\/pnas.1004618107","article-title":"Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry","volume":"107","author":"Mercer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0090","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O\u2019Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ctrv.2009.08.001","article-title":"Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions","volume":"35","author":"Ocana","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1742-4658.2009.07449.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy","volume":"277","author":"Okamoto","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0105","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1006\/viro.1993.1092","article-title":"Transforming growth factor alpha. Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits","volume":"192","author":"Opgenorth","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/135965350501000110","article-title":"Tubular cell apoptosis and cidofovir-induced acute renal failure","volume":"10","author":"Ortiz","year":"2005","journal-title":"Antivirus Ther."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0115","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1462-5822.2009.01327.x","article-title":"Vaccinia-induced epidermal growth factor receptor-MEK signaling and the anti-apoptotic protein F1L synergize to suppress cell death during infection","volume":"11","author":"Postigo","year":"2009","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1634\/theoncologist.2009-0225","article-title":"Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer","volume":"15","author":"Scagliotti","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mcp.2009.10.008","article-title":"Multicolour, multiplex real-time PCR assay for the detection of human-pathogenic poxviruses","volume":"24","author":"Schroeder","year":"2010","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.antiviral.2010.11.006_bib0130","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small cell lung cancer harbouring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1042\/BJ20060509","article-title":"Differential role played by the MEK\/ERK\/EGR-1 pathway in orthopoxviruses vaccinia and cowpox biology","volume":"398","author":"Silva","year":"2006","journal-title":"Biochem J."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0140","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterisation of wild-type and cidofovirresistant strains of camelpox, cowpox, monkeypox and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0145","first-page":"531007","article-title":"In vitro efficacy of ST246 against smallpox and monkeypox","author":"Smith","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0150","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1469-0691.2002.00525.x","article-title":"Smallpox\u2014eradicated, but a growing terror threat","volume":"8","author":"Tegnell","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0155","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1111\/j.1742-4658.2005.05006.x","article-title":"Substrate specificity of vaccinia virus thymidylate kinase","volume":"272","author":"Topalis","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0160","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1093\/emboj\/17.20.5948","article-title":"Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network","volume":"17","author":"Tzahar","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0165","first-page":"145","article-title":"Declaration of global eradication of smallpox","volume":"55","author":"World Health Organization (WHO)","year":"1980","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI200523220","article-title":"Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction","volume":"115","author":"Yang","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2010.11.006_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354210008089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354210008089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T03:26:49Z","timestamp":1685849209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354210008089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0166354210008089"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2010.11.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}